JP2022104553A - LIPに基づいてUMODを修飾した尿中のNeu5Gcを識別する尿路上皮癌の検査用キット、およびその製造方法 - Google Patents
LIPに基づいてUMODを修飾した尿中のNeu5Gcを識別する尿路上皮癌の検査用キット、およびその製造方法 Download PDFInfo
- Publication number
- JP2022104553A JP2022104553A JP2021192080A JP2021192080A JP2022104553A JP 2022104553 A JP2022104553 A JP 2022104553A JP 2021192080 A JP2021192080 A JP 2021192080A JP 2021192080 A JP2021192080 A JP 2021192080A JP 2022104553 A JP2022104553 A JP 2022104553A
- Authority
- JP
- Japan
- Prior art keywords
- lip
- umod
- solution
- precipitate
- neu5gc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FDJKUWYYUZCUJX-AJKRCSPLSA-N N-glycoloyl-beta-neuraminic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-AJKRCSPLSA-N 0.000 title claims abstract description 37
- 210000002700 urine Anatomy 0.000 title claims abstract description 35
- 238000012360 testing method Methods 0.000 title claims abstract description 33
- FDJKUWYYUZCUJX-UHFFFAOYSA-N N-glycolyl-beta-neuraminic acid Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1NC(=O)CO FDJKUWYYUZCUJX-UHFFFAOYSA-N 0.000 title claims abstract description 30
- 230000002485 urinary effect Effects 0.000 title claims abstract description 16
- 201000009030 Carcinoma Diseases 0.000 title claims abstract description 12
- 101000749634 Homo sapiens Uromodulin Proteins 0.000 title claims abstract 5
- 102100040613 Uromodulin Human genes 0.000 title claims abstract 5
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000000243 solution Substances 0.000 claims abstract description 37
- 238000001514 detection method Methods 0.000 claims abstract description 36
- 229910052693 Europium Inorganic materials 0.000 claims abstract description 32
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 claims abstract description 32
- 238000009739 binding Methods 0.000 claims abstract description 26
- 239000004005 microsphere Substances 0.000 claims abstract description 25
- 241000283973 Oryctolagus cuniculus Species 0.000 claims abstract description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 20
- 108010090804 Streptavidin Proteins 0.000 claims abstract description 19
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 17
- 239000012528 membrane Substances 0.000 claims abstract description 11
- 229920001213 Polysorbate 20 Polymers 0.000 claims abstract description 10
- 239000007983 Tris buffer Substances 0.000 claims abstract description 10
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims abstract description 10
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims abstract description 10
- 239000011780 sodium chloride Substances 0.000 claims abstract description 10
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000002105 nanoparticle Substances 0.000 claims abstract description 9
- 241000283707 Capra Species 0.000 claims abstract description 8
- 239000000020 Nitrocellulose Substances 0.000 claims abstract description 8
- 229920001220 nitrocellulos Polymers 0.000 claims abstract description 8
- 239000000835 fiber Substances 0.000 claims abstract description 5
- 229920000728 polyester Polymers 0.000 claims abstract description 5
- 238000005507 spraying Methods 0.000 claims abstract description 5
- 238000011068 loading method Methods 0.000 claims abstract description 4
- 239000002244 precipitate Substances 0.000 claims description 32
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 18
- 239000000872 buffer Substances 0.000 claims description 15
- 229960002685 biotin Drugs 0.000 claims description 11
- 239000011616 biotin Substances 0.000 claims description 11
- 239000003755 preservative agent Substances 0.000 claims description 11
- 230000002335 preservative effect Effects 0.000 claims description 11
- 235000020958 biotin Nutrition 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 239000011259 mixed solution Substances 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 238000007865 diluting Methods 0.000 claims description 5
- 238000009210 therapy by ultrasound Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
- 102000009027 Albumins Human genes 0.000 claims description 4
- 108010088751 Albumins Proteins 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 4
- 108010036650 Immunoproteins Proteins 0.000 claims description 4
- 102000012214 Immunoproteins Human genes 0.000 claims description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 4
- 230000000903 blocking effect Effects 0.000 claims description 4
- 238000011033 desalting Methods 0.000 claims description 4
- 230000001605 fetal effect Effects 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 abstract 2
- 102000018614 Uromodulin Human genes 0.000 description 43
- 108010027007 Uromodulin Proteins 0.000 description 43
- 239000000203 mixture Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 11
- 206010044412 transitional cell carcinoma Diseases 0.000 description 11
- 206010005003 Bladder cancer Diseases 0.000 description 9
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 8
- 201000005112 urinary bladder cancer Diseases 0.000 description 8
- 241000235789 Hyperoartia Species 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000012148 binding buffer Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000003761 preservation solution Substances 0.000 description 3
- 210000001635 urinary tract Anatomy 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 208000023747 urothelial carcinoma Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010058524 Bladder cyst Diseases 0.000 description 1
- 101710151559 Crystal protein Proteins 0.000 description 1
- 206010063057 Cystitis noninfective Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- SUHQNCLNRUAGOO-UHFFFAOYSA-N N-glycoloyl-neuraminic acid Natural products OCC(O)C(O)C(O)C(NC(=O)CO)C(O)CC(=O)C(O)=O SUHQNCLNRUAGOO-UHFFFAOYSA-N 0.000 description 1
- FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000007825 activation reagent Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 201000007433 ureter carcinoma Diseases 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
活性化カルボキシル化ユーロピウム蛍光ナノ微小球を調製するステップと、
活性化カルボキシル化ユーロピウム蛍光ナノ微小球と濃度が1.41mg/mLのストレプトアビジンSAと濃度が5mg/mLのウサギIgGとを2:3:0.5の体積比で混合した後、結合緩衝液を加えて活性化カルボキシル化ユーロピウム蛍光ナノ微小球を2mg/mLの濃度に希釈して、37℃で2時間反応させるステップと、
反応液を4℃、15000×gの条件下で15分間遠心分離して沈殿物Aを取るステップと、
沈殿物Aに洗浄液を加えて超音波処理を行って再懸濁し、4℃、15000×gの条件下で15分間遠心分離して沈殿物Bを取るステップと、
沈殿物Bにブロッキング液を加えて超音波処理を行って再懸濁し、微小球懸濁液を得るステップと、
4℃、15000×gの条件下で微小球懸濁液を15分間遠心分離して沈殿物Cを取るステップと、
沈殿物Cに保存液を加えて超音波処理を行って再懸濁し、4℃、15000×gの条件下で15分間遠心分離して沈殿物Dを取るステップと、
沈殿物Dを保存液で2mg/mLの濃度に希釈するステップであって、前記保存液は、pHが7.8であり、再蒸留水を溶媒とし、25mmol/LのTris baseと、0.15mol/Lの塩化ナトリウムと、1wt%のウシ胎児アルブミンと、0.05wt%のTween-20と、5wt%のトレハロースとを含むステップと、を含む。
1mLのカルボキシル化ユーロピウム蛍光ナノ微小球の活性化緩衝液を試験管に加え、ボルテックスミキサーで十分に混合してカルボキシル化ユーロピウム蛍光ナノ微小球を懸濁し、4℃、15000×gの条件下で15分間遠心分離して上清液をマイクロピペットで吸い取り、このステップをもう1回繰り返す。カルボキシル化ユーロピウム蛍光ナノ微小球はThermo生物会社から購入した。
本発明により提供する尿路上皮癌の検査用キットを用いて、正常なヒト639例、良性疾患25例(膀胱炎症8例、膀胱嚢胞7例、膀胱ポリープ6例、腎炎4例)、尿路上皮癌患者99例(膀胱癌52例、腎臓癌20例、前立腺癌27例)の尿検体を検査測定した。結果を図1に示す。図1に示すように、正常なヒトの尿検体においてLIP特異的に識別される、UMOD糖タンパク質を修飾したNeu5Gcの含有量は67.63±9.31ng/mgであり、良性疾患25例の尿検体においてLIP特異的に識別される、UMOD糖タンパク質を修飾したNeu5Gcの含有量は70.71±8.20ng/mgであって、正常な人に比べて有意差はない。この結果は、泌尿器系癌のスクリーニングにおいて、尿路の炎症などの良性の問題がある場合、LIP特異的に識別される、UMOD糖タンパク質を修飾したNeu5Gcの含有量が正常な人に比べて差はなく、偽陽性の結果が発生しないことを示す。膀胱癌患者52例の尿検体においてLIP特異的に識別される、UMOD糖タンパク質を修飾したNeu5Gcの含有量が260.25±29.38ng/mgであり、腎癌患者20例の含有量は280.54±11.81ng/mg、前立腺癌患者27例の含有量は264.34±30.63ng/mgである。従って、本発明の検査キットは、尿路上皮癌の診断に優れた特異性を備える。
(付記1)
捕捉試薬と検出用緩衝液と試験紙とを備え、前記捕捉試薬は、ビオチン化結合のヤツメウナギ免疫タンパク質LIPであり、前記検出用緩衝液は、50mMのTris base、0.15MのNaCl、0.01%のTween-20及び7.5%のBSAを含んでなり、前記試験紙は、底板を有し、前記底板上には左から右の順で試料投入パッド、蛍光微小球結合釈放パッド、ニトロセルロース膜及び吸水パッドを段階状に順次固定され、前記蛍光微小球結合釈放パッドは、ユーロピウム蛍光ナノ粒子とストレプトアビジンSA及びウサギIgGの結合液をポリエステル繊維上に吹き付けることにより調製され、前記ニトロセルロース膜には左から右の順でUMODモノクローナル抗体から構成された検出バンドとヤギ抗ウサギIgGから構成された参照バンドが順次設けられる、ことを特徴とするLIPに基づいてUMODを修飾した尿中のNeu5Gcを識別する尿路上皮癌の検査用キット。
濃度が0.5mg/mLであるヤツメウナギ免疫タンパク質LIPの水溶液とビオチンを1mL:2mgの投与量の比率で室温で十分に混合して混合液を得、混合液を脱塩カラムで純化してビオチン化結合のヤツメウナギ免疫タンパク質LIPを得る、ことを特徴とする付記1記載のLIPに基づいてUMODを修飾した尿中のNeu5Gcを識別する尿路上皮癌の検査用キット。
ユーロピウム蛍光ナノ粒子とストレプトアビジンSA及びウサギIgGの結合液は以下の調製方法に従って調製され、前記調製方法は、
活性化カルボキシル化ユーロピウム蛍光ナノ微小球を調製するステップと、
前記活性化カルボキシル化ユーロピウム蛍光ナノ微小球と濃度が1.41mg/mLのストレプトアビジンSAと濃度が5mg/mLのウサギIgGとを2:3:0.5の体積比で混合した後、結合緩衝液を加えて前記活性化カルボキシル化ユーロピウム蛍光ナノ微小球を2mg/mLの濃度に希釈して、37℃で2時間反応させるステップと、
反応液を4℃、15000×gの条件下で15分間遠心分離して沈殿物Aを取るステップと、
前記沈殿物Aに洗浄液を加えて超音波処理を行って再懸濁し、4℃、15000×gの条件下で15分間遠心分離して沈殿物Bを取るステップと、
前記沈殿物Bにブロッキング液を加えて超音波処理を行って再懸濁し、微小球懸濁液を得るステップと、
4℃、15000×gの条件下で前記微小球懸濁液を15分間遠心分離して沈殿物Cを取るステップと、
前記沈殿物Cに保存液を加えて超音波処理を行って再懸濁し、4℃、15000×gの条件下で15分間遠心分離して沈殿物Dを取るステップと、
前記沈殿物Dを保存液で2mg/mLの濃度に希釈するステップであって、前記保存液は、pHが7.8であり、再蒸留水を溶媒とし、25mmol/Lの Tris baseと、0.15mol/Lの塩化ナトリウムと、1wt%のウシ胎児アルブミンと、0.05wt%のTween-20と、5wt%のトレハロースとを含むステップと、を含む、ことを特徴とする付記1又は付記2記載のLIPに基づいてUMODを修飾した尿中のNeu5Gcを識別する尿路上皮癌の検査用キット。
Claims (3)
- 捕捉試薬と検出用緩衝液と試験紙とを備え、前記捕捉試薬は、ビオチン化結合のヤツメウナギ免疫タンパク質LIPであり、前記検出用緩衝液は、50mMのTris base、0.15MのNaCl、0.01%のTween-20及び7.5%のBSAを含んでなり、前記試験紙は、底板を有し、前記底板上には左から右の順で試料投入パッド、蛍光微小球結合釈放パッド、ニトロセルロース膜及び吸水パッドを段階状に順次固定され、前記蛍光微小球結合釈放パッドは、ユーロピウム蛍光ナノ粒子とストレプトアビジンSA及びウサギIgGの結合液をポリエステル繊維上に吹き付けることにより調製され、前記ニトロセルロース膜には左から右の順でUMODモノクローナル抗体から構成された検出バンドとヤギ抗ウサギIgGから構成された参照バンドが順次設けられる、ことを特徴とするLIPに基づいてUMODを修飾した尿中のNeu5Gcを識別する尿路上皮癌の検査用キット。
- 濃度が0.5mg/mLであるヤツメウナギ免疫タンパク質LIPの水溶液とビオチンを1mL:2mgの投与量の比率で室温で十分に混合して混合液を得、混合液を脱塩カラムで純化してビオチン化結合のヤツメウナギ免疫タンパク質LIPを得る、ことを特徴とする請求項1記載のLIPに基づいてUMODを修飾した尿中のNeu5Gcを識別する尿路上皮癌の検査用キット。
- ユーロピウム蛍光ナノ粒子とストレプトアビジンSA及びウサギIgGの結合液は以下の調製方法に従って調製され、前記調製方法は、
活性化カルボキシル化ユーロピウム蛍光ナノ微小球を調製するステップと、
前記活性化カルボキシル化ユーロピウム蛍光ナノ微小球と濃度が1.41mg/mLのストレプトアビジンSAと濃度が5mg/mLのウサギIgGとを2:3:0.5の体積比で混合した後、結合緩衝液を加えて前記活性化カルボキシル化ユーロピウム蛍光ナノ微小球を2mg/mLの濃度に希釈して、37℃で2時間反応させるステップと、
反応液を4℃、15000×gの条件下で15分間遠心分離して沈殿物Aを取るステップと、
前記沈殿物Aに洗浄液を加えて超音波処理を行って再懸濁し、4℃、15000×gの条件下で15分間遠心分離して沈殿物Bを取るステップと、
前記沈殿物Bにブロッキング液を加えて超音波処理を行って再懸濁し、微小球懸濁液を得るステップと、
4℃、15000×gの条件下で前記微小球懸濁液を15分間遠心分離して沈殿物Cを取るステップと、
前記沈殿物Cに保存液を加えて超音波処理を行って再懸濁し、4℃、15000×gの条件下で15分間遠心分離して沈殿物Dを取るステップと、
前記沈殿物Dを保存液で2mg/mLの濃度に希釈するステップであって、前記保存液は、pHが7.8であり、再蒸留水を溶媒とし、25mmol/Lの Tris baseと、0.15mol/Lの塩化ナトリウムと、1wt%のウシ胎児アルブミンと、0.05wt%のTween-20と、5wt%のトレハロースとを含むステップと、を含む、ことを特徴とする請求項1又は請求項2記載のLIPに基づいてUMODを修飾した尿中のNeu5Gcを識別する尿路上皮癌の検査用キット。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011574376.5 | 2020-12-28 | ||
CN202011574376.5A CN112763713B (zh) | 2020-12-28 | 2020-12-28 | 基于LIP识别尿液中修饰UMOD的Neu5Gc检验尿路上皮癌的试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP7081861B1 JP7081861B1 (ja) | 2022-06-07 |
JP2022104553A true JP2022104553A (ja) | 2022-07-08 |
Family
ID=75695993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021192080A Active JP7081861B1 (ja) | 2020-12-28 | 2021-11-26 | LIPに基づいてUMODを修飾した尿中のNeu5Gcを識別する尿路上皮癌の検査用キット、およびその製造方法 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP7081861B1 (ja) |
CN (1) | CN112763713B (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114167060B (zh) * | 2021-11-25 | 2022-08-05 | 辽宁师范大学 | 一种肝癌生物标志物及检测肝癌的试剂盒 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009545322A (ja) * | 2006-08-02 | 2009-12-24 | ザ ユーエービー リサーチ ファウンデーション | 規定された抗原特異性の可溶性モノクロナール可変性リンパ球受容体に関連する方法および組成物 |
WO2013078425A1 (en) * | 2011-11-22 | 2013-05-30 | University Of Maryland, Baltimore | Lambodies with high affinity and selectivity for glycans and uses therefor |
CN103554242A (zh) * | 2013-10-23 | 2014-02-05 | 辽宁师范大学 | 七鳃鳗李蛋白、制备方法及在制备预防和***疾病药物中的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102590491B (zh) * | 2012-02-06 | 2014-12-10 | 中国人民解放军第三军医大学第一附属医院 | 一种用于早期筛查或辅助诊断泌尿***疾病的检测试剂盒、检测方法及其用途 |
CN108709994A (zh) * | 2018-05-29 | 2018-10-26 | 吉林大学 | 一种n-羟乙酰神经氨酸快速检测试纸及检测方法 |
-
2020
- 2020-12-28 CN CN202011574376.5A patent/CN112763713B/zh active Active
-
2021
- 2021-11-26 JP JP2021192080A patent/JP7081861B1/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009545322A (ja) * | 2006-08-02 | 2009-12-24 | ザ ユーエービー リサーチ ファウンデーション | 規定された抗原特異性の可溶性モノクロナール可変性リンパ球受容体に関連する方法および組成物 |
WO2013078425A1 (en) * | 2011-11-22 | 2013-05-30 | University Of Maryland, Baltimore | Lambodies with high affinity and selectivity for glycans and uses therefor |
CN103554242A (zh) * | 2013-10-23 | 2014-02-05 | 辽宁师范大学 | 七鳃鳗李蛋白、制备方法及在制备预防和***疾病药物中的应用 |
Non-Patent Citations (3)
Title |
---|
PANG, Y., ET AL.: "A novel protein derived from lamprey supraneural body tissue with efficient cytocidal actions agains", CELL COMMUNICATION AND SIGNALING, vol. 15, no. 42, JPN6022005337, 2017, pages 1 - 16, ISSN: 0004706755 * |
PANG, Y., ET AL.: "Crystal structure of a cytocidal protein from lamprey and its mechanism of action in the selective k", CELL COMMUNICATION AND SIGNALING, vol. 17, no. 54, JPN6022005338, 2019, pages 1 - 20, ISSN: 0004706756 * |
WEISS, G. L., ET AL.: "Architecture and function of human uromodulin filaments in urinary tract infections", SCIENCE, vol. 369, JPN6022005336, 21 August 2020 (2020-08-21), pages 1005 - 1010, ISSN: 0004706754 * |
Also Published As
Publication number | Publication date |
---|---|
JP7081861B1 (ja) | 2022-06-07 |
CN112763713A (zh) | 2021-05-07 |
CN112763713B (zh) | 2022-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200171084A1 (en) | Brain specific exosome based diagnostics and extracorporeal therapies | |
WO2006047928A1 (fr) | Préparation et applications de puces immunodétectrices pour la détection de cellules cancéreuses | |
JP2019060880A (ja) | 移植拒絶反応、神経変性疾患又はうつ病と特に関連する潜在的炎症のインビトロ早期検出方法 | |
CN112379096A (zh) | 一种外泌体膜蛋白作为结肠癌诊断标志物的应用以及结肠癌早期诊断试剂盒 | |
JP7081861B1 (ja) | LIPに基づいてUMODを修飾した尿中のNeu5Gcを識別する尿路上皮癌の検査用キット、およびその製造方法 | |
EP3243076A1 (en) | Methods for detecting a marker for active tuberculosis | |
JP2779178B2 (ja) | 標的リガンド用アッセイの感度を高める方法 | |
JPS6057254A (ja) | 免疫学的測定法による糖脂質の定量方法 | |
CN109991417A (zh) | 一种结核病的免疫标志物及应用 | |
KR102172016B1 (ko) | 항-cyfra21-1 자가항체-항원 결합체 및 cyfra21-1 항원 마커의 검출방법 및 이들 마커의 비율을 이용한 폐암 진단키트 | |
CN109633163B (zh) | 降钙素原/c反应蛋白二合一检测试剂盒 | |
WO2023104059A1 (zh) | 一种循环肿瘤细胞的检测材料、检测器以及检测方法 | |
JPH0479899A (ja) | ヒト及び動物における環状粒子及び悪性腫瘍の存在を検出する生体外の方法及びプローブ | |
CN111610331B (zh) | 一种用于早期食管癌筛查的血清学检测试纸条 | |
EP3358352A1 (en) | Method for estimating pathological tissue diagnosis result (gleason score) of prostate cancer | |
JPH01105160A (ja) | 異常応答リンパ球の検出方法並びにこれに用いる検出用試薬及びキット | |
JPH0616048B2 (ja) | フィブロネクチンの免疫学的測定 | |
CN108872605A (zh) | 一种美洲锥虫病的检测试剂盒及其检测方法 | |
CN111638347B (zh) | Mgo和go快速定量联合检测装置及其制备方法 | |
CN108414305A (zh) | 一种用于结核感染t细胞测定的样本处理方法和处理剂 | |
Li et al. | Immunofluorescence lateral chromatography in combination with detection of hypersensitive C-reactive protein and procalcitonin levels in patients with mental disease associated with coronavirus 2019 disease infection | |
RU2144190C1 (ru) | Способ диагностики стафилококковой инфекции | |
WO2020233572A1 (zh) | 多肽磁性纳米颗粒、其制备方法及应用 | |
RU2702000C2 (ru) | Способ диагностики вируса простого герпеса | |
JP3542245B2 (ja) | 糖尿病もしくは糖尿病合併症用マーカーとしての使用および免疫試薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211209 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211209 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20211209 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220425 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220517 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220519 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7081861 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |